Listing & Compliance Notices

Nixxy, Inc. received a nasdaq delisting notice notice regarding shareholders (rules 5810(c)(2)(A)).

“February 22, 2024, Nasdaq issued the Company a letter informing the company that since it did not hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year-end, it no longer complies with Listing Rules and that following Listing Rule 5810(c)(2)(A), Nasdaq is not permitted to consider the Company’s plan for regaining compliance, and accordingly, that this matter serves as an additional basis for delisting. The Company filed a Hearing Request with Nasdaq to review these matters. On February 22, 2024, the Company received a response that the Hearing would”

Nixxy, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5810(c)(2)(A)).

“February 16, 2024, Nasdaq issued the Company a letter of a staff determination of delisting procedure. On February 22, 2024, Nasdaq issued the Company a letter informing the company that since it did not hold an annual meeting of shareholders within twelve months of the end of the Company’s fiscal year-end, it no longer complies with Listing Rules and that following Listing Rule 5810(c)(2)(A), Nasdaq is not permitted to consider the Company’s plan for regaining compliance, and accordingly, that this matter serves as an additional basis for delisting. The Company filed a Hearing Request with Na”

Evoke Pharma Inc received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 21, 2024, Evoke Pharma, Inc. (the “Company”) received a letter from the Nasdaq Stock Market staff indicating that, for the last thirty consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until August 19, 2024, to regain compliance. The letter states that the Nasdaq staff will provide written notif”

AIR T INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5450(b)(1)(A), 5450(b)(2), 5450(b)(3)).

“received a deficiency letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing set forth in Nasdaq Listing Rule 5450(b)(1)(A). Nasdaq Listing Rule 5450(b)(1)(A) requires listed companies to maintain stockholders’ equity of at least $10,000,000 (the “Stockholders’ Equity Requirement”). The Company has identified its history of stock buybacks as a significant contributing cause, given the direct impact stock bu”

TOMI Environmental Solutions, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 15, 2024, TOMI Environmental Solutions, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for the preceding 30 consecutive business days, the closing bid price for the Company’s common stock, par value $0.01 per share (the “Common Stock”) was below the minimum $1.00 per share requirement for continued inclusion on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The notification received has no immediate effect on”

Nauticus Robotics, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5550(b)(2)).

“February 15, 2024, Nauticus Robotics, Inc. (the “Company”) received written notice from Nasdaq notifying it that the market value of the listed securities of the Company had not met the minimum $35 million requirement for the previous 30 business days, as required for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(b)(2). The notice has no immediate impact on the listing of the Company’s common stock and warrants, which will continue to be listed and trade on Nasdaq subject to the Company’s continued compliance with the other listing requirements of Nasdaq Rules. The Company’s s”

iPower Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“February 21, 2024, the Company received formal approval from Nasdaq granting it an additional 180 days, or until August 19, 2024 (the “Compliance Date”), to regain compliance with the Bid Price Requirement. If at any time before the Compliance Date the closing bid price for the Company’s Common Stock is at least $1.00 for a minimum of 10 consecutive business days, the Staff will provide the Company written confirmation that it has regained compliance with the Bid Price Requirement. If the Company does not regain compliance with the Bid Price Requirement by the Compliance Date, the Staff will p”

Charge Enterprises, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“ry 29, 2024. Nasdaq determined that the Company was not eligible for the Extension Request and reached its decision to commence delisting proceedings of the Common Stock because the closing bid price of the Common Stock has closed below $0.10 and may soon trigger delisting under Nasdaq Listing Rule 5810(c)(3)(A)(iii). The Company does not intend to appeal the staff’s determination and, accordingly, the Company expects that the Common Stock will be delisted. The Company announced that it anticipates that the Common Stock will be quoted on the OTC Pink Market under the symbol “CRGE.” 7.01. Regul”

Blue World Acquisition Corp received a nasdaq compliance regained notice regarding market value (rules 5450(b)(2)(A)).

“February 20, 2024, the Company received a written notice from the staff of Nasdaq (the “ Staff ”) notifying the Company that the Staff has determined that for the last 22 consecutive business days, from January 18, 2024 to February 16, 2024, the Company’s MVLS has been $50 million or greater. Accordingly, the Company has regained compliance with the MVLS Rule and the Staff has indicated that the matter is now closed. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto d”

OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(3)).

“February 15, 2024, Bellevue Life Sciences Acquisition Corp. (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the “ Minimum Public Holders Requirement ”). In accordance with Nasdaq rules, the Company has 45 calendar days, or until April 1, 2024, to submit a plan to regain compliance with the Minimum Public Holders Requirement. If the”

Clean Energy Special Situations Corp. received a nasdaq delisting notice notice regarding late filing.

“February 14, 2024, the Company received a formal notice (the “ Formal Notice ”) from the Staff that, based upon the Company’s non-compliance with the Exception, the Company’s securities were subject to delisting unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “ Plan ”). The Company plans to timely request a hearing before the Plan, which will stay the suspension of the Company’s securities only for a period of 15 days from the date of the request. When the Company requests a hearing, it also plans on requesting a stay of the suspension, pending the hearing. T”

CNS Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)).

“February 14, 2024, the Staff notified the Company that it had not complied with the Listing Rule and as such did not meet the terms of the extension. The Staff letter stated that unless the Company timely requests a hearing before a Hearings Panel (the “Panel”), the Company would be subject to delisting. Accordingly, the Company intends to timely request a hearing before the Panel. The hearing request will automatically stay any suspension or delisting action pending the hearing and the expiration of any additional extension period granted by the Panel following the hearing. In that regard, th”

STAR EQUITY HOLDINGS, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“partment of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that, for a period of 30 consecutive business days, the bid price of its common stock closed below the minimum bid price of $1.00 per share required for continued listing on The Nasdaq Global Market pursuant to Nasdaq Listing Rule 5450(a)(1). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), and as indicated in the Letter, the Company has 180 calendar days, or until August 12, 2024, to regain compliance with the minimum bid price requirement. The Letter further provided that if at any time during this 180-day period, the”

MultiSensor AI Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“February 13, 2024, MultiSensor AI Holdings, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with the requirement to maintain a minimum Market Value of Listed Securities (“MVLS”) of $50 million, as set forth in Nasdaq Listing Rule 5450(b)(2)(A) (the “MVLS Requirement”), because the MVLS of the Company was below $50 million for the 30 consecutive business days prior to the date of the Notice. Nasdaq further indicated that, as of the date of the Notice”

NKGen Biotech, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605, 5605(b)(1)(A)).

“February 13, 2024, NKGen Biotech, Inc. (the “Company”) received a written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) dated February 13, 2024, indicating that, as a result of Alana McNulty’s resignation from the Board of Directors of the Company (the “Board”) and audit committee of the Board (the “Audit Committee”), effective February 4, 2024, that the Company is not currently in compliance with Nasdaq Listing Rule 5605, which requires that (i) a majority of the Board be comprised of independent directors and (ii) the Audit Committee is comprised of at least three indepen”

CONX Corp. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2)).

“sly disclosed on the Current Report on Form 8-K filed by CONX Corp., a Nevada corporation (the “Company”) with the Securities and Exchange Commission on August 18, 2023, on August 14, 2023, the staff of The Nasdaq Stock Market LLC (“Nasdaq”) notified the Company that it no longer meets Listing Rule 5550(b)(2) (the “Rule”) requiring the Company to maintain a minimum market value of listed securities (“MVLS”) of $35 million. The notice was based on a review of the Company’s MVLS for the past 30 consecutive business days. Nasdaq’s listing rules provided the Company a compliance period of 180 cale”

GeoVax Labs, Inc. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 16, 2024, the Company received a letter from Nasdaq stating that Nasdaq has determined the Company to have regained compliance with The Nasdaq Capital Market listing requirements and that, consequently, the scheduled Hearing has been cancelled. The Company’s securities will continue to be listed and traded on The Nasdaq Stock Market.”

ProSomnus, Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(A), 5810(c)(3)(C)).

“continued listing. Additionally, as previously disclosed, the Company received separate written notices from Nasdaq, indicating that the Company was no longer in compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”), and that the Company was no longer in compliance with the minimum Market Value of Publicly Held Shares of $15,000,000 for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(b)(2)(C) (the “MVPHS Requirement”). The”

ECD Automotive Design, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“February 14, 2024, ECD Automotive Design Inc., a Delaware corporation (the “Company”), received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s listed securities failed to comply with the $50,000,000 market value of listed securities (“MVLS”) requirement for continued listing on The Nasdaq Global Market in accordance with Nasdaq Listing Rule 5450(b)(2)(A) based upon the Company’s MVLS for the 30 consecutive business days prior to the date of the Notice. The Notice has no immediate effect on the listing of the Company’s securities on Nasdaq and in”

TREASURE GLOBAL INC received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 15, 2024, Treasure Global Inc (the “Company”) received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company has not regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires a minimum bid price of at least $1.00 per share (the “Minimum Bid Price Rule”) and that Nasdaq determined that the common stock of the Company will be scheduled for delisting unless the Company requests an appeal of this determination from the Nasdaq Hearings Panel (the “Panel”). On February 16, 2024, the Company submitted a hearing”

Finance of America Companies Inc. received a nyse noncompliance notice notice regarding minimum bid price (rules 802.01C).

“February 12, 2024, Finance of America Companies Inc. (“Finance of America” or the “Company”) received a notice (the “Notice”) from the NYSE, indicating the Company is not in compliance with Section 802.01C of the NYSE Listed Company Manual because as of February 9, 2024, the average closing price of the Company’s Class A Common Stock was less than $1.00 over a consecutive 30 trading-day period. The Notice has no immediate effect on the listing of the Class A Common Stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements. Furthermore, the Noti”

Fisker Inc./DE received a nyse deficiency notice notice regarding minimum bid price (rules 802.01C).

“February 15, 2024, Fisker Inc. (the “Company,” “we,” “us” or “our”) was notified by the New York Stock Exchange (the “NYSE”) that it is not in compliance with Section 802.01C of the NYSE Listed Company Manual because the average closing price of the Company’s common stock was less than $1.00 over a consecutive 30 trading-day period. The notice does not result in the immediate delisting of the Company’s common stock from the NYSE. Pursuant to Section 802.01C, the Company has a period of six months from receipt of the notice to regain compliance with the minimum stock price listing requirement.”

Datavault AI Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).

“November 17, 2023, the Staff notified the Company that it was not in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on Nasdaq to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing (the “Stockholders’ Equity Requirement”). The Company reported stockholders’ equity (deficit) of ($885,000) in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, and, as a result, did not satisfy the Stockholders’ Equity Requirement pursuant to Listing Rule 5550(b)(1). On February 14, 2024, the Company received notice (the “February”

Datavault AI Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A)(iii)).

“February 14, 2024, the Company received notice (the “February 14 Letter”) from the Staff that the Staff had determined that as of February 14, 2024, the Company’s securities had a closing bid price of $0.10 or less for ten consecutive trading days triggering application of Listing Rule 5810(c)(3)(A)(iii) which states in part: if during any compliance period specified in Rule 5810(c)(3)(A), a company’s security has a closing bid price of $0.10 or less for ten consecutive trading days, the Listing Qualifications Department shall issue a Staff Delisting Determination under Rule 5810 with respect”

KULR Technology Group, Inc. received a nyse_american noncompliance notice notice regarding minimum bid price (rules 1003(f)(v)).

“February 12, 2024, KULR Technology Group, Inc. (the “Company”) received a letter (the “Letter”) from the staff of NYSE American LLC (the “Exchange”) stating that the Company’s securities’ performance of trading price is below compliance criteria pursuant to Section 1003(f)(v) of the NYSE American Company Guide, which the Exchange determined to be a 30-trading day average of less than $0.20 per share. The Company’s continued listing is predicated on it demonstrating sustained price improvement within a reasonable period of time, which the Exchange has determined to be no later than August 12, 2”

Adaptimmune Therapeutics PLC received a nasdaq compliance regained notice regarding minimum bid price (rules 5450(a)(1)).

“February 16, 2024, Adaptimmune Therapeutics plc (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Select Market. Consequently, the Company is now in compliance with all applicable listing standards, and it will continue to be listed on The Nasdaq Global Select Market. ​ The Company was previously notified by Nasdaq on August 31, 2023 that it was not in compliance with the minimum bid price requir”

Jaguar Health, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iii)).

“February 15, 2024, the Company received a letter from the Staff notifying the Company that as of February 14, 2024, the Company's common stock had a closing bid price of $0.10 or less for 10 consecutive trading days. Accordingly, the Company is subject to the provisions contemplated under Nasdaq Listing Rule 5810(c)(3)(A)(iii) (the “Low Priced Stocks Rule”). As a result, the Staff has issued a letter notifying the Company of its determination to delist the Company’s securities from Nasdaq effective as of the opening of business on February 26, 2024, unless the Company requests an appeal before”

SELLAS Life Sciences Group, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 14, 2024, SELLAS Life Sciences Group, Inc. (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days the Company’s common stock did not maintain a minimum closing bid price of $1.00 per share as required by Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The notice has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on The Nasdaq Capital Market under the symbol “SLS” at this time. In accordance with Nas”

YIELD10 BIOSCIENCE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“September 25, 2023, Yield10 received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance with this listing requirement. To regain compliance, the closing bid price of the Company’s common stock must be $1.00 per share or more for a minimum of 10 consecutive business day”

YIELD10 BIOSCIENCE, INC. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(a)(2), 5810(c)(3)(A)).

“nce with Nasdaq requirements. Also as previously disclosed, on September 25, 2023, Yield10 received a deficiency letter from the Staff notifying the Company that it was not in compliance with the requirement to maintain a minimum bid price of at least $1.00 per share pursuant to Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until March 25, 2024, to regain compliance with this listing requirement. To regain compliance, the closing bid price of the Company’s common stock must be $1.00”

LIFECORE BIOMEDICAL, INC. DE received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“February 13, 2024, Lifecore Biomedical, Inc., a Delaware corporation (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that Nasdaq has initiated a process which could result in the delisting of the Company’s securities from Nasdaq as a result of the Company not being in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires listed companies to timely file all required periodic financial reports with the Securities and Exchang”

BIOLASE, INC received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)).

“February 13, 2024, the Company received notice from the Staff of the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Staff had determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the “Rule”). The Rule requires a minimum $2,500,000 stockholders’ equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations. As previously announced, on November 14, 2023, the Company received a deficiency letter from the Nasdaq notifying it that, based on its stockholders’”

Vaxxinity, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 9, 2024, Vaxxinity, Inc. (the “Company”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”) with respect to its Class A Common Stock, which requires the Company to maintain a minimum bid price of $1.00 per share for continued listing on The Nasdaq Global Market (the “Notice”). The Company has until August 7, 2024, which is 180 calendar days from the date of the Notice (the “Compliance Period”), to regain compliance with the”

Novo Integrated Sciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 9, 2024, Novo Integrated Sciences, Inc., a Nevada corporation (the “Company”), received a notification letter (the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq. Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency con”

PETMED EXPRESS INC received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“February 13, 2024, the Company received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, as a result of not having timely filed the Form 10-Q with the SEC, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”), which requires timely filing of all required periodic financial reports with the SEC. The Notice has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq. The Notice indicated that the Company must submit a plan to regain compliance with the Listing Rule within 60 calendar days and”

QUANTUM CORP /DE/ received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“February 13, 2024, Quantum Corporation (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications staff of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company’s failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the “Quarterly Report”) with the Securities and Exchange Commission (the “SEC”). On February 14, 2024, the Company filed a Notification of Late Filing on Form 12b-25 with the SEC indicating that the filing of”

OMNIQ Corp. received a nasdaq deficiency notice notice regarding market value (rules 5550(b)(2), 5810(c)(3)(C)).

“February 8, 2024, the Company received a new notice (the “Notice”) from the Staff that the Company has not regained compliance with Nasdaq Listing Rule 5550(b)(2), and thus, unless the Company requests an appeal of this determination from the Staff, the Company’s common stock will be suspended at the opening of business on February 20, 2024, which will remove the Company’s securities from listing and registration on Nasdaq. As of the date of this current report on Form 8-K, and in accordance with the Nasdaq Listing Rule 5800 Series, the Company may appeal the Staff’s determination to the heari”

Bright Green Corp received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(a)).

“int the Company would have an opportunity to appeal the delisting determination to a Nasdaq Listing Qualifications Panel (the “Panel”), but there can be no assurance that the Panel would grant the Company’s request for continued listing. As a condition of the Approval imposed by Nasdaq Listing Rule 5810(c)(3)(a), the Company notified Nasdaq that it would seek to implement a reverse stock split, if necessary, to regain compliance with the Bid Price Rule. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be si”

Atlantic Coastal Acquisition Corp. received a nasdaq delisting notice notice regarding other (rules 5250(c)(1)).

“curities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. On August 17, 2023, and November 20, 2023, Staff notified the Company that it did not comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1) (the “Rule”) because it had not filed its Form 10-Q for the period ended June 30, 2023, and its Form 10-Q for the period ended September 30, 2023 (the “Delinquent Reports”). Based on its review and the materials submitted by the Company on October 31, 2023, the Staff granted the Company a”

Atlantic Coastal Acquisition Corp. received a nasdaq delisting notice notice regarding late filing (rules 5250(c)(1)).

“curities and Exchange Commission (the “SEC”), which will remove the Company’s securities from listing and registration on The Nasdaq Stock Market. On August 17, 2023, and November 20, 2023, Staff notified the Company that it did not comply with Nasdaq’s filing requirements set forth in Listing Rule 5250(c)(1) (the “Rule”) because it had not filed its Form 10-Q for the period ended June 30, 2023, and its Form 10-Q for the period ended September 30, 2023 (the “Delinquent Reports”). Based on its review and the materials submitted by the Company on October 31, 2023, the Staff granted the Company a”

Chicken Soup for the Soul Entertainment, Inc. received a nasdaq noncompliance notice notice regarding market value (rules 5450(b)(1)(C)).

“February 8, 2024, Chicken Soup for the Soul Entertainment Inc. (the “ Company ”) received written notice (the “ Letter ”) from the Nasdaq Stock Market LLC (“ Nasdaq ”) indicating that the Company was not in compliance with the continued listing standards of Nasdaq (the “ Rules ”) because the Nasdaq Rule 5450(b)(1)(C) requires listed securities to maintain a minimum market value of publicly held shares (“MVPHS”) of $5,000,000 and, based upon Nasdaq’s review of the MVPHS of the Company’s Class A Common Stock, $0.0001 par value per share (“common stock”), for the last 30 consecutive business days”

Sunworks, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2024, as a result of the Bankruptcy Filing, the Company received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company’s common stock will be delisted from The Nasdaq Stock Market. Accordingly, trading of the Company’s common stock will be suspended no later than the opening of business on February 15, 2024. Nasdaq Listing Rule 5110(b) states in part that “Nasdaq may use its discretionary authority under Rule 5100 to suspend or terminate the listing of a Company that has filed for protection under any provision of the federal bankruptcy”

Sunworks, Inc. received a nasdaq delisting notice notice regarding other (rules 5110(b)).

“February 6, 2024, as a result of the Bankruptcy Filing, the Company received a written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company’s common stock will be delisted from The Nasdaq Stock Market. Accordingly, trading of the Company’s common stock will be suspended no later than the opening of business on February 15, 2024. Nasdaq Listing Rule 5110(b) states in part that “Nasdaq may use its discretionary authority under Rule 5100 to suspend or terminate the listing of a Company that has filed for protection under any provision of the federal bankruptcy”

META MATERIALS INC. received a nasdaq compliance regained notice regarding minimum bid price (rules 5550(a)(2)).

“February 12, 2024, the Company received a letter from Nasdaq notifying the Company that it has regained compliance with the Minimum Bid Price Requirement, and consequently, the previously scheduled hearing was cancelled by the Nasdaq Hearings Panel. The Company is currently in full compliance with Nasdaq listing requirements and will continue trading on Nasdaq. On February 13, 2024, the Company issued a press release announcing it has regained Nasdaq compliance. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K, and is incorporated herein by reference.”

Charge Enterprises, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(b)(1)(C), 5450(a)(1)).

“August 22, 2023, the Company received a letter from Nasdaq notifying the Company that it was no longer in compliance with Nasdaq Listing Rule 5450(b)(1)(C) because the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s Common Stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its Common Stock from the Nasdaq Global Market to the Nasdaq Capital Market. As a result of the Approval, the Comp”

Global Interactive Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 5, 2024, Hanryu Holdings, Inc. (the “Company”) received a deficiency letter from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company’s common stock has been below the minimum $1.00 per share required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Nasdaq deficiency letter has no immediate effect on the listing of the Company’s common stock, a”

Cycurion, Inc. received a nasdaq deficiency notice notice regarding other (rules 5550(a)(4)).

“February 6, 2024, Western Acquisition Ventures Corp., a Delaware corporation (the “Company”), received a notification letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Company no longer meets the minimum 500,000 publicly held shares requirement for continued listing on The Nasdaq Capital Market set forth in Nasdaq Listing Rule 5550(a)(4). The notification received has no immediate effect on the listing of the Company’s common stock on Nasdaq. Under Nasdaq Listing Rules, the Company has 45 calendar dates, or until March”

Perception Capital Corp. III received a nasdaq deficiency notice notice regarding other (rules 5620(a)).

“February 6, 2024, PC3 received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that PC3 has not yet held an annual meeting of shareholders within twelve months after its fiscal year end, and therefore no longer complies with Nasdaq Listing Rule 5620(a). The Notice is only a notification of deficiency, not of imminent delisting, and has no current effect on the listing or trading of the PC3’s securities on the Nasdaq Capital Market. The Notice states that PC3 has 45 calendar days, or until March 25, 2024, to subm”

Momentus Inc. received a nasdaq compliance regained notice regarding stockholders equity.

“February 7, 2024, Momentus Inc. (the “Company”) received an approval letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the Nasdaq staff approved the Company’s application to transfer the listing of its Class A common stock (the “Common Stock”) and warrants from the Nasdaq Global Market to the Nasdaq Capital Market. On this basis, the previous listing deficiency regarding minimum stockholder’s equity will be closed. The Common Stock and the warrants will continue to trade under the symbols “MNTS” and “MNTSW,” respectively, a”

Kalaris Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 9, 2024, AlloVir, Inc. (“AlloVir”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of AlloVir’s common stock was below $1.00 per share for 30 consecutive business days, and that, therefore, AlloVir is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market. The notice from Nasdaq has no immediate effect on the listing of AlloVir’s common stock, and the common stock will continue to be listed on the Nasdaq Global Select Market under the”